Stockscreener 앱 받기
1.63
3.82%
0.06
시간 외 거래:
1.63
Lava Therapeutics Nv 주식(LVTX)의 최신 뉴스
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 0.7% - Defense World
Investors in LAVA Therapeutics (NASDAQ:LVTX) from a year ago are still down 16%, even after 44% gain this past week - Yahoo Lifestyle Australia
LAVA Therapeutics (NASDAQ:LVTX) Receives Buy Rating from HC Wainwright - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com India
Macquarie starts Ensign Group stock coverage with outperform rating By Investing.com - Investing.com India
Barclays sets Charles River Labs stock target with Equalweight rating By Investing.com - Investing.com India
Citi reaffirms sell on Dr. Reddy's shares amid acquisition deal By Investing.com - Investing.com
Jefferies sets buy rating on Syndax stock By Investing.com - Investing.com UK
UBS starts Hydro One stock coverage with neutral rating By Investing.com - Investing.com UK
Lava Therapeutics shares hold target with Buy rating - Investing.com India
JPMorgan starts PagerDuty stock with neutral rating amid 'competitive landscape' By Investing.com - Investing.com Australia
Cava group director Bosserman sells over $2.7 million in company stock By Investing.com - Investing.com Canada
Goldman Sachs sets target on Paramount shares, initiates with sell By Investing.com - Investing.com
Transocean adjusts share capital and treasury shares By Investing.com - Investing.com
LAVA Therapeutics Shareholders Approve Key ResolutionsTipRanks.com - TipRanks
Metric Analysis: LAVA Therapeutics NV (LVTX)'s Key Ratios in the Limelight – DWinneX - The Dwinnex
Kayne Anderson BDC stock gets Market Perform from KBW, notes stable industry focus By Investing.com - Investing.com
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
Kinsale Capital's president and COO sells shares worth over $579,000 By Investing.com - Investing.com South Africa
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
BioCardia secures patent for cardiac delivery catheter By Investing.com - Investing.com India
Karyopharm CEO sells shares worth $3,556 By Investing.com - Investing.com
3.66%
1.11%
자본화:
|
볼륨(24시간):